Lianhuan Pharmaceutical (600513.SH) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Zhitong Finance App News, Lianhuan Pharmaceutical (600513.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for evastine oral solution approved and issued by the State Drug Administration. Ebastine is a second-generation H1 receptor histamine antagonist. This product is more selective for histamine H1 receptors than first-generation H1 receptor antagonists. It is an H1 receptor antagonist with strong selectivity and long-lasting action. It is suitable for symptomatic treatment of allergic rhinitis (seasonal and perennial) and chronic idiopathic urticaria with or without allergic conjunctivitis.
This time, the company obtained the “Drug Registration Certificate” for the oral solution of evastine, which further enriches the company's product line and helps enhance the market competitiveness of the company's products. Since this variety has received a new drug registration certificate, it is not expected to have a significant impact on the company's recent business performance.